ClinicalTrials.gg
Not yet recruitingNCT07625124Updated Jun 4, 2026

A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease

A Phase 2 interventional study of RCI001 Ophthalmic Solution and Placebo Ophthalmic Solution in Dry Eye, sponsored by Rudacure. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Rudacure · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2 clinical study designed to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution compared with placebo in participants with dry eye disease.

The study will enroll adults with dry eye disease. After a 2-week run-in period with placebo ophthalmic solution, eligible participants will be randomly assigned to receive either 0.25% RCI001 Ophthalmic Solution or placebo ophthalmic solution in both eyes for 4 weeks. Study treatment will be administered either twice daily or four times daily, depending on the assigned dosing regimen.

The main purpose of the study is to determine whether RCI001 improves the signs and symptoms of dry eye disease compared with placebo. The primary assessments include total corneal fluorescein staining and ocular discomfort at Day 28. Safety will be assessed through eye examinations, visual acuity, intraocular pressure, drop comfort, and adverse event monitoring.

Read the detailed description

This is a multi-center, randomized, double-masked, placebo-controlled Phase 2 study evaluating 0.25% RCI001 Ophthalmic Solution in participants with dry eye disease.

The study will include approximately 6 weeks of participation for each participant, consisting of a 2-week run-in period followed by a 4-week treatment period. Approximately 400 participants are expected to be screened, and approximately 200 eligible participants will be randomized, with approximately 50 participants assigned to each treatment group.

During the run-in period, participants who qualify at screening will receive placebo ophthalmic solution in both eyes according to either a twice-daily or four-times-daily dosing regimen. At the end of the run-in period, eligible participants will be randomized to continue the same dosing frequency and receive either 0.25% RCI001 Ophthalmic Solution or placebo ophthalmic solution bilaterally for 4 weeks.

The four treatment groups are:

0.25% RCI001 Ophthalmic Solution twice daily; placebo ophthalmic solution twice daily; 0.25% RCI001 Ophthalmic Solution four times daily; and placebo ophthalmic solution four times daily.

The study will include four scheduled visits: screening at Day -14, baseline/randomization at Day 1, follow-up at Day 14, and end-of-treatment/study exit at Day 28. Controlled Adverse Environment (CAE) assessments will be used as part of the study procedures.

The primary efficacy endpoints are total corneal fluorescein staining and ocular discomfort assessed before CAE exposure at Day 28. Secondary efficacy assessments include additional ocular staining measures, conjunctival redness, Schirmer's test, tear film break-up time, Ocular Surface Disease Index, ocular discomfort scores, visual analog scale symptoms, and daily symptom diary data.

Safety assessments include visual acuity, slit-lamp biomicroscopy, drop comfort, adverse event monitoring, intraocular pressure, and dilated fundoscopy. The study is designed to compare RCI001 with the corresponding placebo dosing regimen and to evaluate the optimal dosing frequency of RCI001 in the treatment of the signs and symptoms of dry eye disease.

02

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • RCI001
  • Phase 2
  • Rudacure
03

In context

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

This study's planned enrollment of 200 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

Rudacure is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age at the Screening Visit (Visit 1), of either gender and any race.
  2. Able and willing to provide written .
  3. Willing and able to comply with all study procedures.
  4. Patient-reported history of dry eye for at least 6 months prior to Visit 1.
  5. History of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1.
  6. Best corrected visual acuity (BCVA) of 0.7 logMAR or better (Snellen equivalent of 20/100 or better) in each eye at Visit 1.
  7. At least one eye, the same eye, must satisfy all criteria for Schirmer's Test, corneal fluorescein staining, conjunctival lissamine green staining, conjunctival redness, and CAE response.
  8. Female participants of must have a negative urine pregnancy test and must use adequate throughout the study period. For non-sexually active females, abstinence may be regarded as an adequate method of birth control.

Exclusion criteria

Exclusion Criteria:

  1. slit-lamp findings at Visit 1, including active blepharitis, meibomian gland dysfunction, severe lid margin inflammation, or active ocular allergies requiring therapeutic treatment, and/or findings that in the opinion of the investigator may interfere with study parameters. Participants with moderate to severe meibomian gland dysfunction, in the opinion of the investigator, are not eligible.
  2. Ongoing ocular infection, including bacterial, viral, or fungal infection, or active ocular inflammation at Visit 1.
  3. Contact lens wear within 7 days of Visit 1 or anticipated use of contact lenses during the study.
  4. LASIK surgery within the last 12 months.
  5. Female participant who is pregnant, nursing, or planning a pregnancy.
  6. Female participant of who is unwilling to submit a urine pregnancy test at Visit 1 and Visit 4, or at an early termination visit.
  7. Female participant of childbearing potential who is not using an acceptable method of . Acceptable methods include hormonal contraceptives, mechanical contraception with spermicide and a barrier method, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as adequate; however, if the participant becomes sexually active during the study, she must agree to use adequate birth control for the remainder of the study.
  8. Known allergy and/or sensitivity to the test article or its components.
  9. Any condition or situation that, in the investigator's opinion, may put the participant at significant risk, may confound study results, or may interfere significantly with participation in the study.
  10. Current enrollment in an drug or device study or use of an investigational drug or device within 30 days of Visit 1.
  11. Unable or unwilling to follow instructions, including participation in all study assessments and visits.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    RCI001 Ophthalmic Solution BID

    Participants will receive 0.25% RCI001 Ophthalmic Solution, one drop in each eye twice daily (BID), for 4 weeks.

    Drug: RCI001 Ophthalmic Solution

  • Placebo comparator
    Placebo Ophthalmic Solution BID

    Participants will receive placebo ophthalmic solution, one drop in each eye twice daily (BID), for 4 weeks.

    Drug: Placebo Ophthalmic Solution

  • Experimental
    RCI001 Ophthalmic Solution QID

    Participants will receive 0.25% RCI001 Ophthalmic Solution, one drop in each eye four times daily (QID), for 4 weeks.

    Drug: RCI001 Ophthalmic Solution

  • Placebo comparator
    Placebo Ophthalmic Solution QID

    Participants will receive placebo ophthalmic solution, one drop in each eye four times daily (QID), for 4 weeks.

    Drug: Placebo Ophthalmic Solution

Interventions

  • DrugRCI001 Ophthalmic Solution

    RCI001 Ophthalmic Solution is a topical ophthalmic investigational drug containing 0.25% RCI001. Participants assigned to RCI001 treatment will receive one drop in each eye either twice daily (BID) or four times daily (QID), depending on the assigned treatment arm, for 4 weeks.

    Also known as: 0.25% RCI001 Ophthalmic Solution

  • DrugPlacebo Ophthalmic Solution

    Placebo Ophthalmic Solution is a topical ophthalmic vehicle solution that has the same formulation as RCI001 Ophthalmic Solution but does not contain the active ingredient, RCI001. Participants assigned to placebo treatment will receive one drop in each eye either twice daily (BID) or four times daily (QID), depending on the assigned treatment arm, for 4 weeks.

    Also known as: Vehicle Ophthalmic Solution

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Corneal Fluorescein Staining Score at Day 28

    Change from baseline in total corneal fluorescein staining score in the study eye, assessed before Controlled Adverse Environment (CAE) exposure at Day 28 using the Ora Calibra Corneal and Conjunctival Staining Scale. Each ocular surface region is graded from 0 to 4, where 0 indicates no staining and 4 indicates confluent staining. The total score is the sum of the assessed regions, and higher scores indicate more staining and worse ocular surface disease.

    Time frame: Baseline to Day 28 (Week 4)

  2. Change From Baseline in Ocular Discomfort Score at Day 28

    Change from baseline in ocular discomfort score in the study eye, assessed before Controlled Adverse Environment (CAE) exposure at Day 28 using the Ora Calibra Ocular Discomfort Scale for Dry Eye. The scale ranges from 0 to 4, where 0 indicates no discomfort and 4 indicates constant discomfort. Higher scores indicate worse ocular discomfort.

    Time frame: Baseline to Day 28 (Week 4)

Secondary outcomes

  1. Change From Baseline in Fluorescein Staining Scores by Region

    Change from baseline in fluorescein staining scores by ocular region, including central, superior, inferior, temporal, and nasal regions, as well as summary staining scores, assessed using the Ora Calibra Corneal and Conjunctival Staining Scale. Each region is graded from 0 to 4, where 0 indicates no staining and 4 indicates confluent staining. Higher scores indicate more staining and worse ocular surface disease.

    Time frame: Baseline to Day 14 and Day 28

  2. Change From Baseline in Conjunctival Lissamine Green Staining Scores by Region

    Change from baseline in conjunctival lissamine green staining scores by ocular region, including central, superior, inferior, temporal, and nasal regions, as well as summary staining scores, assessed using the Ora Calibra Corneal and Conjunctival Staining Scale. Each region is graded from 0 to 4, where 0 indicates no staining and 4 indicates confluent staining. Higher scores indicate more staining and worse ocular surface disease.

    Time frame: Baseline to Day 14 and Day 28

  3. Change From Baseline in Conjunctival Redness Score

    Change from baseline in conjunctival redness score assessed using the Ora Calibra Conjunctival Redness Scale for Dry Eye. The scale ranges from 0 to 4, where 0 indicates normal without vasodilation and 4 indicates severe redness. Higher scores indicate worse conjunctival redness.

    Time frame: Baseline to Day 14 and Day 28

  4. Change From Baseline in Schirmer's Test Score

    Change from baseline in Schirmer's test value. Schirmer's test measures tear production using the length of wetting on a Schirmer test strip after 5 minutes. The unit of measure is millimeters (mm), and higher values indicate greater tear production.

    Time frame: Baseline to Day 14 and Day 28

  5. Change From Baseline in Tear Film Break-Up Time

    Change from baseline in tear film break-up time (TFBUT). TFBUT measures the time from eye opening to the first appearance of tear film break-up after fluorescein instillation. The unit of measure is seconds, and higher values indicate greater tear film stability.

    Time frame: Baseline to Day 14 and Day 28

  6. Change From Baseline in Ocular Surface Disease Index Score

    Change from baseline in Ocular Surface Disease Index (OSDI) score assessed before Controlled Adverse Environment (CAE) exposure. The OSDI is a participant-reported questionnaire scored from 0 to 100, where higher scores indicate greater dry eye symptom severity and vision-related functional impairment.

    Time frame: Baseline to Day 14 and Day 28

  7. Change From Baseline in Ocular Discomfort Scale Score

    Change from baseline in ocular discomfort score assessed using the Ora Calibra Ocular Discomfort Scale for Dry Eye. The scale ranges from 0 to 4, where 0 indicates no discomfort and 4 indicates constant discomfort. Higher scores indicate worse ocular discomfort.

    Time frame: Baseline to Day 14 and Day 28

  8. Change From Baseline in Visual Analog Scale Symptom Scores

    Change from baseline in participant-reported dry eye symptom scores assessed using a visual analog scale (VAS). The VAS is scored from 0 to 100, where higher scores indicate greater symptom severity.

    Time frame: Baseline to Day 14 and Day 28

  9. Change From Baseline in Ocular Discomfort and 4-Symptom Questionnaire Score

    Change from baseline in participant-reported ocular discomfort and dry eye symptom scores assessed using the Ora Calibra Ocular Discomfort and 4-Symptom Questionnaire for Dry Eye. Participants rate overall ocular discomfort, burning, dryness, grittiness, and stinging on a 0 to 5 scale, where 0 indicates none and 5 indicates worst. Higher scores indicate worse symptoms.

    Time frame: Baseline to Day 14 and Day 28

  10. Change From Baseline in Daily Symptom Diary Scores

    Change from baseline in participant-reported daily dry eye symptom diary scores collected during the treatment period using the Ora Calibra Ocular Discomfort and 4-Symptom Questionnaire for Dry Eye. Symptoms are rated on a 0 to 5 scale, where 0 indicates none and 5 indicates worst. Higher scores indicate worse symptoms.

    Time frame: Baseline to Day 28

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs leading to premature discontinuation. Adverse events will be coded using MedDRA and summarized by treatment group.

    Time frame: From first dose through Day 28

  2. Change From Baseline in Visual Acuity

    Change from baseline in best-corrected visual acuity (BCVA). The unit of measure is change in visual acuity value, such as logMAR or ETDRS-based score, as collected in the study.

    Time frame: Baseline to Day 28

  3. Change From Baseline in Intraocular Pressure

    Change from baseline in intraocular pressure (IOP) measured in each eye by contact tonometry. The unit of measure is mmHg.

    Time frame: Baseline to Day 28

  4. Slit-Lamp Biomicroscopy Findings

    Number and percentage of participants with slit-lamp biomicroscopy findings, including clinically significant and non-clinically significant ocular findings, as determined by the investigator.

    Time frame: Baseline to Day 28

  5. Dilated Fundoscopy Findings

    Number and percentage of participants with dilated fundoscopy findings, including clinically significant and non-clinically significant posterior segment findings, as determined by the investigator.

    Time frame: Baseline to Day 28

  6. Mean Ora Calibra Drop Comfort Scale Score After Initial Dosing

    Mean subject-reported drop comfort score assessed for each eye using the Ora Calibra Drop Comfort Scale after initial dosing at Visit 2. The Ora Calibra Drop Comfort Scale is an 11-point scale ranging from 0 to 10, where 0 indicates very comfortable and 10 indicates very uncomfortable.

    Time frame: Immediately after initial dosing and at 1 and 2 minutes after initial dosing

  7. Subject-Reported Drop Comfort Descriptors After Initial Dosing

    Subject-reported drop comfort descriptors assessed using the Ora Calibra Drop Comfort Questionnaire at 3 minutes after initial dosing at Visit 2. Participants will select words that best describe how the eye drops feel in both eyes. The unit of measure will be the number and percentage of participants selecting each descriptor.

    Time frame: 3 minutes after initial dosing

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP; OPUS-2 Investigators. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Ophthalmology. 2015 Dec;122(12):2423-31. doi: 10.1016/j.ophtha.2015.08.001. Epub 2015 Sep 11. PubMed 26365210 ↗
  • Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA. PERSIST: Physician's Evaluation of Restasis((R)) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971-6. doi: 10.2147/OPTH.S30261. Epub 2012 Nov 28. PubMed 23226002 ↗
  • Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol. 2009 Jun;127(6):763-8. doi: 10.1001/archophthalmol.2009.103. PubMed 19506195 ↗
  • Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405-12. doi: 10.2147/opth.s5555. Epub 2009 Jul 14. PubMed 19688028 ↗
  • Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA. TFOS DEWS II pathophysiology report. Ocul Surf. 2017 Jul;15(3):438-510. doi: 10.1016/j.jtos.2017.05.011. Epub 2017 Jul 20. PubMed 28736340 ↗

Individual participant data

Plan to share: No — Individual participant data will not be made available to other researchers. The study is sponsored by RudaCure Corporation and involves an investigational drug product. De-identified individual participant-level data are not planned for external sharing due to participant confidentiality, informed consent, regulatory, legal, and proprietary considerations. Aggregate study results may be disclosed through ClinicalTrials.gov, publications, and/or regulatory submissions, as applicable.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2027; primary completion for Jun 2028, 9 months later.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 9 months is above that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
Jun 4, 2026
StartEst.
Sep 1, 2027
Primary completionEst.
Jun 30, 2028
CompletionEst.
Aug 30, 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07625124
Lead sponsor
Rudacure
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Sep 1, 2027 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Jun 4, 2026

Study contacts

Yuseung Ha
Contact
yuseung.ha@rudacure.com
+8207075991644
Seunghoon Kim
Contact
sh.kim@rudacure.com
Yuseung Ha
study director · Rudacure

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion